Cancer, neonatal care, and genetic disorders dominate crowdfunding in India

Q: How long will it take to read this news story?

The story "Cancer, neonatal care, and genetic disorders dominate crowdfunding in India" has 772 words across 30 sentences, which will take approximately 4 - 7 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Cancer, neonatal care, and genetic disorders dominate crowdfunding in India" was covered 2 days ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 277 news stories per day. It's most recent story was published 2 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #27535656</li><li>URL: https://beamstart.com/news/cancer-neonatal-care-and-genetic-17435850593966</li></ul>

Business Standard Logo Business Standard 2d ago

Cancer, neonatal care, and genetic disorders dominate crowdfunding in India - Business Standard

Quick Summary:

While India is still in its early stages, the potential for medical crowdfunding is immense, paving the way for a more inclusive and financially sustainable healthcare ecosystem,” said Jain.

Medical crowdfunding is emerging as a vital healthcare financing solution in India, helping bridge the gap created by high medical expenses and limited insurance.

We have seen strong interest from communities in the United States, United Kingdom, Middle East and Southeast Asia in supporting Indian medical fundraisers, especially for cancer, rare diseases, gene therapy and organ transplants.